Global Peptide Therapeutics Market Outlook to 2025: Key Applications (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, Dermatology), Type (Generic, Innovative), Manufacturers (In-house, Outsourced), Route of Administration(Parenteral, Oral, Pulmonary, Mucosal and Others), Regional Segmentation, Pipeline Analysis, Regulatory Landscape, Competitive Dynamics, M&A Insights, Segment Forecast And Conclusion

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The Global peptide therapeutics market was valued at $ 35.2 Billion in 2017 and is forecast to grow at a modest xx.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ xx6.6 Billion. Signiant number of new peptides are entering into the market. 8 in 2012 to xx in 2018. Rising incidence of cancer and metabolic disorder pushing demand for biologic and biosimilars. Demand from developing countries pushing for low cost biosimilars. This ultimately increasing the demand for both innovative and generic peptides.

 

We are observing upswing due to recent advances in genomics with new targets identified for peptide therapy and safer compared to small molecule. Strong pipeline is also another factor driving the market. In addition, advancements in the processes of manufacturing peptides is expected to enhance further development of therapeutics.

 

End users need support at all stages from the peptide manufacturer such as from preclinical to commercialization. Peptide manufacturer having comprehensive GMP from milligrams to 100 KG and ability to provide services ranging from development, optimization and validation to scalable and economic process are going to lead the market.

.

 

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Global Peptide Therapeutics Products”

 

Estimated Average peptide product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the Global, the peptide therapeutics products are available at USD XXXX. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products. The cost of a Peptide Therapeutics facility would be very high. At current prices, the capital cost might be expected to be in the range $XX-XX Million with the annual operating costs of the order of $1 Million.

.

 

Application Insight

 

We have segmented the market based on the application types such as Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain and Dermatology. Cell-penetrating peptides (CPP) have served to deliver various molecules and particles into cells.  Vaccine made up of peptides use tumor associated antigens to target cancer. Natriuretic peptides used as biomarkers for the purpose of personalized heart failure treatments and maintain heart pressure and volume, as well as regulating cardiovascular remodeling pathways.

 

Manufacturer Type Insight

 

We have segmented the market based on manufacturer type as Generic and Innovative. Innovative peptide dominating the market in terms of revenue and held a market share of 72%. However, demand for generic medicine from emerging countries will create demand for generic peptide. Recent loss of patents of many branded medicines will also create opportunity for generic peptides. Custom Peptide are also in demand and offers numerous options for synthesis platforms, purity levels, modifications, and formats to meet a variety of research needs.

Given the current state of technology for peptide synthesis and characterization, FDA believes it is now possible for an ANDA applicant to demonstrate that the active ingredient in a proposed generic synthetic peptide drug product (proposed generic synthetic peptide) is the “same” as the active ingredient in a previously approved peptide of rDNA origin.

 

Route of Administration-

 

We have segmented the market based on route of administration as parenteral, oral, pulmonary, mucosal and others. Parenteral route is the most commonly employed method of administration for therapeutic proteins and peptides. However, requirement of frequent injections due to short in vivo half-life results in poor patient compliance. Oral route offers the advantages of self-administration with a high degree of patient acceptability and compliance. Some of the distinct advantages of pulmonary route will be large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium.

 

Mucosal route (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular and oral cavity) have distinct advantages such as possible bypass of the first pass effect, avoidance of pre-systemic elimination of gastrointestinal tract. A better enzymatic flora for drug absorption.

 

Regional Segmentation

 

North America accounted for over xx% revenue share in 2017. The key reasons attributed for the high share include strong reimbursement framework, highly skilled medical professionals, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end therapeutic drugs and high emphasis on outcome is expected to boost the usage rates over the forecast period.

We have observed strong market during the years 2004-2012 with the development of new peptides and generics. Europe and is expected to grow during the forecast period with rising demand from Asian and South American markets.

 

Merger and Acquisition Insight

 

We are observing some unique merger and acquisition in this space. In 2017, Polypeptide Group announced acquisition of the peptides business and operations of Lonza in Belgium. Bachem is planning to acquire a mid-size peptide manufacturer in Europe in recent time.

 

Top Players & Company Share

 

We have profiled major players in the market as Bachem Holding AG, Eli Lilly and Company, Pfizer Inc.,     Amgen Inc., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical, Lonza Inc., Sanofi, Bristol-Myers Squibb(BMS), AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, Novo Nordisk A/S, PolyPeptide Laboratories. With recent development in technology, we are observing some unique new players into the market.

 

Market Segmentation

 

GLOBAL Peptide Therapeutics Market by Application Types (Revenue, USD Million, 2014- 2025)

  • Cancer
  • Cardiovascular Disorder
  • Metabolic Disorder
  • Respiratory Disorder
  • Pain
  • Dermatology

GLOBAL Peptide Therapeutics Market by Approval Status (Revenue, USD Million, 2014 – 2025)

  • Generic
  • Innovator

GLOBAL Peptide Therapeutics Market by Manufacturer Type (Revenue, USD Million, 2014- 2025)

  • In-house
  • Outsourced

GLOBAL Peptide Therapeutics Market by Route of Administration (Revenue, USD Million, 2014- 2025)

  • Parenteral
  • Oral
  • Pulmonary
  • Mucosal
  • Others

GLOBAL Peptide Therapeutics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Peptide Therapeutic Market Overview

  • Disease Landscape
  • Healthcare Expenditure

Chapter 4 Peptide Therapeutic Market Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Major Buying Authorities and Decision-Making Process
  • Key Market Drivers
    • Increasing prevalence of cancer
    • Rising incidences of metabolic disorder
    • Presence of strong product pipeline portfolio
    • Upcoming Biosimilars
  • Key Market Challenges
    • Stringent regulations
    • Overcrowded small manufacturer
    • Pricing
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Peptide Therapeutic Market-PESTEL Analysis

Chapter 5: - Peptide Therapeutic Market by “Type of Application” (USD Million)

  • Peptide Therapeutic Market Landscape by Application Type- 2017 & 2025
    • Cancer
  • Market Landscape Analysis, 2017-2025(USD Mn)
    • Cardiovascular Disorder
  • Market Landscape Analysis, 2017-2025(USD Mn)
    • Cardiovascular Disorder
  • Market Landscape Analysis, 2017-2025(USD Mn)
    • Metabolic Disorder
  • Market Landscape Analysis, 2017-2025(USD Mn)
    • Respiratory Disorder
  • Market Landscape Analysis, 2017-2025(USD Mn)
    • Pain
  • Market Landscape Analysis, 2017-2025(USD Mn)
    • Dermatology
  • Market Landscape Analysis, 2017-2025(USD Mn)
 

Chapter 6: - Peptide Therapeutic Market by “Approval Status” (USD Million)

  • Peptide Therapeutic Market Landscape by Radiation Type- 2017 & 2025
  • Generic
  • Market Landscape Analysis, 2017-2025(USD Mn)
  • Innovator
  • Market Landscape Analysis, 2017-2025(USD Mn)
 

Chapter 7: - Peptide Therapeutic Market by “Manufacturer Type” (USD Million)

  • Peptide Therapeutic Market Landscape by Disease Type- 2017 & 2025
  • In-House
  • Market Landscape Analysis, 2017-2025(USD Mn)
  • Outsourced
  • Market Landscape Analysis, 2017-2025(USD Mn)

Chapter 8: - Peptide Therapeutic Market by “Route of Administration” (USD Million)

  • Peptide Therapeutic Market Landscape by Treatment Type- 2017 & 2025
  • Parenteral
  • Market Landscape Analysis, 2017-2025(USD Mn)
  • Oral
  • Market Landscape Analysis, 2017-2025(USD Mn)
  • Pulmonary
  • Market Landscape Analysis, 2017-2025(USD Mn)
  • Mucosal
  • Market Landscape Analysis, 2017-2025(USD Mn)
  • Others
  • Market Landscape Analysis, 2017-2025(USD Mn)
 

Chapter 9: Regional Market Outlook

 
  • Peptide Therapeutic Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025(USD Mn)
    • U.S. Market Landscape Analysis, 2017-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025(USD Mn)
    • UK Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025(USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia pacific Market Landscape Analysis, 2017-2025(USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2024 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2017-2025
    • South Africa Market Landscape Analysis, 2017-2025
  Chapter 10: Pricing Analysis  
  • Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 11: Peptide Therapeutic Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 12: Peptide Therapeutic Merger & Acquisition Outlook

  • Major licensing deals
  • Factors driving M&A in Peptide Therapeutic market
  • Key trends and future outlook

Chapter 13: Peptide Therapeutic Regulatory & Patent Outlook

  • Regulatory Landscape by Region (U.S., Europe, and RoW)
  • Patent Landscape by Region (U.S., Europe, and RoW)

Chapter 14: Competitive Landscape 

  • Bachem Holding AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Eli Lilly and Company
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Pfizer Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Amgen Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Takeda Pharmaceutical Company Limited.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Aeolus Pharmaceuticals
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Teva Pharmaceutical.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Lonza Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Sanofi
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bristol-Myers Squibb(BMS)
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • AstraZeneca PLC
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • GlaxoSmithKline (GSK)
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Novartis AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Novo Nordisk A/S
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • PolyPeptide Laboratories
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
   

List of Tables

 
  • TABLE 1 Peptide Therapeutic Market - Industry Snapshot & Key Buying Criteria, 2014 - 2024
  • TABLE 2 Global Peptide Therapeutic Market, 2014 – 2024
  • TABLE 3 Global Peptide Therapeutic Market Analysis by Product-2017
  • TABLE 4 Global Peptide Therapeutic Market Analysis by Technology -2017
  • TABLE 5 Global Peptide Therapeutic Market Analysis by Application-2017
  • TABLE 7 Global Peptide Therapeutic Market Analysis by Geography-2017
  • TABLE 8 Global Peptide Therapeutic Market Analysis by Leading Brands-2017
  • TABLE 9 Peptide Therapeutic Market - Key market driver analysis
  • TABLE 10 Peptide Therapeutic Market - Key market restraint analysis
  • TABLE 11 North America Market Peptide Therapeutic Landscape Analysis, 2017-2025(USD Mn)
  • TABLE 12U.S. Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 13 Canada Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 14 Europe Peptide Therapeutic Market Landscape Analysis, 2017-2025(USD Mn)
  • TABLE 15 U.K Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 17 France Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 20 Latin America Peptide Therapeutic Market Landscape Analysis, 2017-2025(USD Mn)
  • TABLE 21 Brazil Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia pacific Peptide Therapeutic Market Landscape Analysis, 2017-2025(USD Mn)
  • TABLE 22 Japan Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 23 China Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 24 India Peptide Therapeutic Market Landscape Analysis, 2017-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017

List of Figures

  • 1 Peptide Therapeutic Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Peptide Therapeutic Market – PESTEL Analysis
  • 7 Peptide Therapeutic Market Share by Product Type, 2017 & 2025
  • 8 Peptide Therapeutic Market Share by Technology Type, 2017 & 2025
  • 9 Peptide Therapeutic Market Share by Application Type, 2017 & 2025
  • 10 Peptide Therapeutic Market Share by Region, 2017 & 2025
 

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of the competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:      
  • The Global peptide therapeutics market was valued at $ 35.2 Billion in 2017 and is forecast to grow at a modest xx.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ xx6.6 Billion.
  • We are observing upswing due to recent advances in genomics with new targets identified for peptide therapy and safer compared to small molecule.
  • We have profiled major players in the market as Bachem Holding AG, Eli Lilly and Company, Pfizer Inc.,     Amgen Inc., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical, Lonza Inc., Sanofi, Bristol-Myers Squibb(BMS), AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, Novo Nordisk A/S, PolyPeptide Laboratories.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involve in the process are as below-

  1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
  2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
  3. Need Gap Analysis- Defining the gap between our scope and availability of information.
  4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
  5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
  6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
  7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The Global peptide therapeutics market was valued at $ 35.2 Billion in 2017 and is forecast to grow at a modest xx.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ xx6.6 Billion. Signiant number of new peptides are entering into the market. 8 in 2012 to xx in 2018. Rising incidence of cancer and metabolic disorder pushing demand for biologic and biosimilars. Demand from developing countries pushing for low cost biosimilars. This ultimately increasing the demand for both innovative and generic peptides.

 

We are observing upswing due to recent advances in genomics with new targets identified for peptide therapy and safer compared to small molecule. Strong pipeline is also another factor driving the market. In addition, advancements in the processes of manufacturing peptides is expected to enhance further development of therapeutics.

 

End users need support at all stages from the peptide manufacturer such as from preclinical to commercialization. Peptide manufacturer having comprehensive GMP from milligrams to 100 KG and ability to provide services ranging from development, optimization and validation to scalable and economic process are going to lead the market.

.

 

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Global Peptide Therapeutics Products”

 

Estimated Average peptide product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the Global, the peptide therapeutics products are available at USD XXXX. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products. The cost of a Peptide Therapeutics facility would be very high. At current prices, the capital cost might be expected to be in the range $XX-XX Million with the annual operating costs of the order of $1 Million.

.

 

Application Insight

 

We have segmented the market based on the application types such as Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain and Dermatology. Cell-penetrating peptides (CPP) have served to deliver various molecules and particles into cells.  Vaccine made up of peptides use tumor associated antigens to target cancer. Natriuretic peptides used as biomarkers for the purpose of personalized heart failure treatments and maintain heart pressure and volume, as well as regulating cardiovascular remodeling pathways.

 

Manufacturer Type Insight

 

We have segmented the market based on manufacturer type as Generic and Innovative. Innovative peptide dominating the market in terms of revenue and held a market share of 72%. However, demand for generic medicine from emerging countries will create demand for generic peptide. Recent loss of patents of many branded medicines will also create opportunity for generic peptides. Custom Peptide are also in demand and offers numerous options for synthesis platforms, purity levels, modifications, and formats to meet a variety of research needs.

Given the current state of technology for peptide synthesis and characterization, FDA believes it is now possible for an ANDA applicant to demonstrate that the active ingredient in a proposed generic synthetic peptide drug product (proposed generic synthetic peptide) is the “same” as the active ingredient in a previously approved peptide of rDNA origin.

 

Route of Administration-

 

We have segmented the market based on route of administration as parenteral, oral, pulmonary, mucosal and others. Parenteral route is the most commonly employed method of administration for therapeutic proteins and peptides. However, requirement of frequent injections due to short in vivo half-life results in poor patient compliance. Oral route offers the advantages of self-administration with a high degree of patient acceptability and compliance. Some of the distinct advantages of pulmonary route will be large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium.

 

Mucosal route (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular and oral cavity) have distinct advantages such as possible bypass of the first pass effect, avoidance of pre-systemic elimination of gastrointestinal tract. A better enzymatic flora for drug absorption.

 

Regional Segmentation

 

North America accounted for over xx% revenue share in 2017. The key reasons attributed for the high share include strong reimbursement framework, highly skilled medical professionals, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end therapeutic drugs and high emphasis on outcome is expected to boost the usage rates over the forecast period.

We have observed strong market during the years 2004-2012 with the development of new peptides and generics. Europe and is expected to grow during the forecast period with rising demand from Asian and South American markets.

 

Merger and Acquisition Insight

 

We are observing some unique merger and acquisition in this space. In 2017, Polypeptide Group announced acquisition of the peptides business and operations of Lonza in Belgium. Bachem is planning to acquire a mid-size peptide manufacturer in Europe in recent time.

 

Top Players & Company Share

 

We have profiled major players in the market as Bachem Holding AG, Eli Lilly and Company, Pfizer Inc.,     Amgen Inc., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical, Lonza Inc., Sanofi, Bristol-Myers Squibb(BMS), AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, Novo Nordisk A/S, PolyPeptide Laboratories. With recent development in technology, we are observing some unique new players into the market.

 

Market Segmentation

 

GLOBAL Peptide Therapeutics Market by Application Types (Revenue, USD Million, 2014- 2025)

  • Cancer
  • Cardiovascular Disorder
  • Metabolic Disorder
  • Respiratory Disorder
  • Pain
  • Dermatology

GLOBAL Peptide Therapeutics Market by Approval Status (Revenue, USD Million, 2014 – 2025)

  • Generic
  • Innovator

GLOBAL Peptide Therapeutics Market by Manufacturer Type (Revenue, USD Million, 2014- 2025)

  • In-house
  • Outsourced

GLOBAL Peptide Therapeutics Market by Route of Administration (Revenue, USD Million, 2014- 2025)

  • Parenteral
  • Oral
  • Pulmonary
  • Mucosal
  • Others

GLOBAL Peptide Therapeutics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6,650